Evidence map›Paper›PMID 24361600›Full record

ArticleNeurobiology of disease2014

Prodegenerative IκBα expression in oligodendroglial α-synuclein models of multiple system atrophy.

Christine L Kragh, Amanda M Gysbers, Edward Rockenstein, Karen Murphy, Glenda M Halliday, Eliezer Masliah, Poul Henning Jensen

Open access · greenAbstract read
In one paragraph

Article in Neurobiology of disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Models of multiple system atrophy.Experimental & molecular medicine · 2019
    Review
  4. Article
  5. Review
  6. Multiple system atrophy: pathogenic mechanisms and biomarkers.Journal of neural transmission (Vienna, Austria : 1996) · 2016
    Review
  7. Animal models of multiple system atrophy.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Christine L KraghDepartment of Biomedicine & Danish Research Institute of Translational Neuroscience-DANDRITE, University of Aarhus, Aarhus, Denmark.
Amanda M GysbersNeuroscience Research Australia, Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia.
Edward RockensteinDepartment of Neurosciences and Pathology, University of California, San Diego, School of Medicine, La Jolla, CA 92093-0624, USA.
Karen MurphyNeuroscience Research Australia, Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia.
Glenda M HallidayNeuroscience Research Australia, Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia.
Eliezer MasliahDepartment of Neurosciences and Pathology, University of California, San Diego, School of Medicine, La Jolla, CA 92093-0624, USA.
Poul Henning JensenDepartment of Biomedicine & Danish Research Institute of Translational Neuroscience-DANDRITE, University of Aarhus, Aarhus, Denmark. Electronic address: phj@biokemi.au.dk.
Aarhus University · DKUniversity of California, San Diego · USUNSW Sydney · AUNeuroscience Research Australia · AU

Funding

VIRUS-INDUCED BRAIN PATHOLOGYP50AG005131 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BREWER, JAMES B · 1985 to 2018
$55.4M
Studies on Diagnosis, Pathophysiology, and Treatment of Autonomic Failure in MSAP01NS044233 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOW, PHILLIP A · 2003 to 2014
$12.4M
a-synuclein clearance strategies for the treatment of Lewy body disease.R37AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MASLIAH, ELIEZER · 2006 to 2014
$2.7M
NIA NIH HHS P50 AG005131NIA NIH HHS R37 AG018440NINDS NIH HHS P01 NS044233
6 · The paper itself

Abstract

Multiple system atrophy is a progressive, neurodegenerative disease characterized by parkinsonism, ataxia, autonomic dysfunction, and accumulation of α-synuclein in oligodendrocytes. To understand how α-synuclein aggregates impact oligodendroglial homeostasis, we investigated an oligodendroglial cell model of α-synuclein dependent degeneration and identified responses linked to the NF-κB transcription factor stress system. Coexpression of human α-synuclein and the oligodendroglial protein p25α increased the expression of IκBα mRNA and protein early during the degenerative process and this was dependent on both aggregation and Ser129 phosphorylation of α-synuclein. This response was prodegenerative because blocking IκBα expression by siRNA rescued the cells. IκBα is an inhibitor of NF-κB and acts by binding and retaining NF-κB p65 in the cytoplasm. The protection obtained by silencing IκBα was accompanied by a strong increase in nuclear p65 translocation indicating that NF-κB activation protects against α-synuclein aggregate stress. In the cellular model, two different phenotypes were observed; degenerating cells retracting their microtubules and resilient cells tolerating the coexpression of α-synuclein and p25α. The resilient cells displayed a significant higher nuclear translocation of p65 and activation of the NF-κB system relied on stress elicited by aggregated and Ser129 phosphorylated α-synuclein. To validate the relationship between oligodendroglial α-synuclein expression and IκBα, we analyzed two different lines of transgenic mice expressing human α-synuclein under the control of the oligodendrocytic MBP promotor (intermediate-expresser line 1 and high-expresser line 29). IκBα mRNA expression was increased in both lines and immunofluorescence microscopy and in situ hybridization revealed that IκBα mRNA and protein is expressed in oligodendrocytes. IκBα mRNA expression was demonstrated prior to activation of microglia and astrocytes in line 1. Human brain tissue affected by MSA displayed increased expression of IκBα and NF-κB p65 in some oligodendrocytes containing glial cytoplasmic inclusions. Our data suggest that oligodendroglial IκBα expression and NF-κB are activated early in the course of MSA and their balance contributes to the decision of cellular demise. Favoring oligodendroglial NF-κB activation may represent a therapeutic strategy for this devastating disease.

Indexed as

alpha-SynucleinAnimalsBrainCells, CulturedGene Expression RegulationHumansI-kappa B ProteinsMice, TransgenicMultiple System AtrophyMyelin Basic ProteinNerve Tissue ProteinsNeurogliaNF-KappaB Inhibitor alphaOligodendrogliaOligonucleotide Array Sequence AnalysisPhosphotransferasesalpha-SynucleinCdk5r1 protein, ratI-kappa B ProteinsMyelin Basic ProteinNerve Tissue ProteinsNF-KappaB Inhibitor alphaNFKBIA protein, humanNfkbia protein, mouseNfkbia protein, ratPhosphotransferasesRNA, Small InterferingIκBαMultiple system atrophyNF-κBOligodendrocytesα-Synuclein

Identifiers

PMID24361600
PMCPMC4943925
OpenAlexW2092189177

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.